)
Edge23 Jan 2026
Death, Taxes, and Garbage: The Story of WM
How Waste Management turned garbage into one of America's most stable business models through landfills, regulation, and nationwide scale.
Takeda Pharmaceutical Company
Takeda Pharmaceutical Company (4502) investor relations material
Takeda Pharmaceutical Company 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary13 Jan, 2026
Strategic transformation, vision, and innovation
Shifted from generics and OTC to an innovation-driven pharmaceutical business, emphasizing digital, cloud, and AI across all operations.
Committed to life-transforming treatments guided by patient, people, and planet values, prioritizing patient, trust, reputation, and business.
U.S. revenue share grew from under 20% to 52%, with operations in 80 countries and $5B annual R&D investment.
R&D now focused on gastroenterology, neuroscience, and oncology, with reduced generic exposure expected until 2030+.
Leadership transition planned, with Julie Kim succeeding Christophe Weber as CEO.
Pipeline and product launches
Eight late-stage assets targeted for launch before 2030, many with breakthrough or orphan status and significant lifecycle management opportunities.
Strategic partnership with Innovent added TAK-928 (immuno-oncology) and TAK-921 (Claudin 18.2 ADC) to the pipeline.
Three major launches—Oveporexton, Rusfertide, and Zasocitinib—planned within the next 18 months, pending regulatory approval.
Fazirsiran (RNA therapy for liver disease) and mezagitamab (CD38 antibody) also advancing.
Several assets have received breakthrough, fast track, or orphan drug designations.
Clinical data and market potential
Oveporexton exceeded phase III expectations, normalizing symptoms in a significant majority of NT1 patients with strong safety and tolerability; launch expected H2 2026.
Rusfertide offers durable hematocrit control and reduced phlebotomy eligibility in polycythemia vera, targeting ~155k diagnosed U.S. patients.
Zasocitinib met all primary and secondary endpoints in Phase 3 for plaque psoriasis, with high efficacy and a favorable safety profile, aiming to double the oral therapy market.
Combined peak revenue potential for the three products estimated at $6B–$10B, offsetting ENTYVIO's expected decline post-2030.
Five additional late-stage assets to further support growth before 2030.
What differentiates Takeda's IL-2/PD-1 bispecific?
Zasocitinib: How to shift oral psoriasis paradigm?
Balance launch investment vs. R&D for margins?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Takeda Pharmaceutical Company earnings date
Q3 202629 Jan, 2026
Takeda Pharmaceutical Company
Next Takeda Pharmaceutical Company earnings date
Q3 202629 Jan, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Takeda Pharmaceutical Company Limited, founded in 1781, is a research-based global company. The Company's segment is engaged in the research and development, manufacturing and marketing of pharmaceutical products. Through its global presence in over 70 countries, the Company offers a range of products to meet unmet medical needs in a variety of therapeutic areas, including gastroenterology, oncology and neuroscience, among others. The Company's business unit includes Gastroenterology Business Unit, Oncology Business Unit and General Medicines Business Unit. GBU's focus is on creating new value in GI diseases to enhance the lives of patients and their families. OBU's focus is on building a portfolio with the potential to serve patients worldwide that address unmet cancers. GMBU focuses on providing innovative treatment options for patients in such disease areas as internal medicine, respiratory, renal and central nervous system.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage